Author:
Schoepf Isabella C.,Riebensahm Carlotta,Becchetti Chiara,Blaser Valentine,Unternährer Céline V.,Banz Vanessa,Hirzel Cédric,Suter-Riniker Franziska M.,Berzigotti Annalisa
Abstract
BACKGROUND AND AIM: Liver transplant recipients show suboptimal vaccine-elicited immune responses to severe acute respiratory coronavirus 2 (SARS-CoV-2) vaccination. This study aimed to assess real-world data on SARS-CoV-2 antibodies after the second and third SARS-CoV-2 vaccination in liver transplant recipients in Switzerland.
METHODS: We enrolled liver transplant recipients who attended regular follow-up visits between 01/07/2021 and 30/04/2022 at the outpatient clinic of the Department of Visceral Surgery and Medicine at Bern University Hospital, Switzerland. Following the Swiss Federal Office of Public Health recommendations, we measured SARS-CoV-2 anti-spike IgG antibodies in 117 liver transplant recipients ≥4 weeks after the second SARS-CoV-2 mRNA vaccination from 07/2021–04/2022. In case of antibody levels of <100 AU/ml, patients received a third vaccination and antibodies were re-measured. Patients with antibody levels of >100 AU/ml were defined as “responders”, those with 12–100 AU/ml as “partial responders” and those with <12 AU/ml as “non-responders”.
RESULTS: After two vaccinations, 36/117 (31%) were responders, 42/117 (36%) were partial responders and 39/117 (33%) were non-responders. The humoral immune response improved significantly after the third vaccination, resulting in 31/55 (56%) responders among the previous partial or non-responders. A total of 26 patients developed COVID-19, of whom two had a moderate or severe course (both non-responders after three doses).
DISCUSSION: One third of liver transplant recipients showed an optimal response following two vaccinations; a third dose achieved a complete antibody response in more than half of partial and non-responders. We observed only one severe course of COVID-19 and no deaths from COVID-19 in the vaccinated liver transplant recipients.
Publisher
SMW Supporting Association
Reference28 articles.
1. Becchetti C, Gschwend SG, Dufour JF, Banz V. Covid-19 in liver transplant recipients: A systematic review. J Clin Med. 2021 Sep;10(17):4015. 10.3390/jcm10174015
2. Becchetti C, Zambelli MF, Pasulo L, Donato MF, Invernizzi F, Detry O, et al.; COVID-LT group. COVID-19 in an international European liver transplant recipient cohort. Gut. 2020 Oct;69(10):1832–40. 10.1136/gutjnl-2020-321923
3. Guarino M, Cossiga V, Loperto I, Esposito I, Ortolani R, Fiorentino A, et al. COVID-19 in liver transplant recipients: incidence, hospitalization and outcome in an Italian prospective double-centre study. Sci Rep. 2022 Mar;12(1):4831. 10.1038/s41598-022-08947-x
4. Swissmedic. Swissmedic erteilt Zulassung für den ersten COVID-19-Impfstoff in der Schweiz. https://www.swissmedic.ch/swissmedic/de/home/news/coronavirus-covid-19/covid-19-impfstoff_erstzulassung.html [accessed: 30 January 2021].
5. Swissmedic. Swissmedic erteilt die Zulassung für den COVID-19 Impfstoff von Moderna. https://www.swissmedic.ch/swissmedic/de/home/news/coronavirus-covid-19/zulassung-covid-19-impfstoff-moderna.html [accessed: 30 January 2021].